Mycovia Pharmaceuticals Inc.   Report issue

For profit Phase 3
Founded: Durham NC United States (2018)

Organization Overview

First Clinical Trial
2018
NCT03562156
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Mycovia Pharmaceuticals Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

fluconazole (diflucan) (1 trial)

oteseconazole (2 trials)

vt-116 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Candidiasis (Phase 3)

Candidiasis, Vulvovaginal (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3